| Active Ingredient | Mifepristone and Misoprostol |
| Brand | Mifegest |
| Country of origin | India |
| Form | Oral Tablet |
Mifegest Tablet is a Combikit medicine containing Mifepristone and Misoprostol. It is taken orally for medical termination of an early pregnancy, typically up to 9 to 10 weeks or 70 days from the first day of your last menstrual period. This medicine should be taken under strict medical guidance to safely end early pregnancy.
Clinical Uses
Mifegest Tablet is primarily used for the medical termination of an early pregnancy. It is taken alone or in combination with other medicines for maximum benefit. Strictly follow the healthcare provider’s instructions regarding its use, as medical assessment and follow-up are important to confirm completion and identify complications.
Dose Options
Mifegest Tablet Kit is available in the strengths 100 MCG and 200 MCG. The right dose is decided by the doctor as suitable for the condition.
How It Works
Mifegest Combikit contains mifepristone and misoprostol, which work together to medically terminate an early pregnancy. Mifepristone works by blocking the action of progesterone, which is an essential hormone for maintaining pregnancy. By this action, the lining of the uterus begins to break down, which helps prevent pregnancy.
Misoprostol is usually taken 24 to 48 hours after mifepristone. It softens and dilates the cervix and stimulates contractions of the uterus. This action helps expel the pregnancy tissue from the uterus through the vagina.
Together, they help terminate early pregnancy and help the uterus to empty its contents.
Side Effects
Side effects of Mifegest Combikit Tablet include:
- Vomiting
- Diarrhea
- Stomach pain
- Dizziness
- Uterine cramping
- Uterine bleeding
- Irregular thickening of the uterine lining
Severe side effects that need immediate medical attention include:
- Heavy vaginal bleeding
- Unusual tiredness or weakness
- Infections
- Pain during urination
Precautions & Warnings
- Consult your doctor about drinking alcohol while taking Mifegest Combikit Tablet.
- Mifegest Tablet should not be used by breastfeeding women as it can cause serious harm to the infant.
- Driving is not recommended while taking Mifegest Tablet as it can increase the risk of vaginal bleeding.
- Confirm pregnancy before taking this medicine.
- Mifegest Tablet should be used in women above 35 years.
- Consult with your doctor before taking this medicine if you have:
- Intrauterine device
- Bleeding disorder
- Mifegest Combikit Tablet should be used with caution in kidney, liver, or heart disease.
Drug Interactions
Inform your doctor about any other medicines you are taking. Mifegest Tablet can interact with certain medicines, including:
- Erythromycin
- Ketoconazole
- Dexamethasone
- Warfarin
- Pimozide
- Phenytoin
- Cyclosporine
- Rifampicin
- Tacrolimus
- Hydrocortisone
Disclaimer
At 5M Biotech India we provide accurate, reliable and expert reviewed information. However, all our content on this platform is intended for informational purposes only and is not professional medical advice, diagnosis or treatment. While we make efforts to maintain accuracy, the information may contain mistakes, omissions or may not reflect the latest developments. Always consult your doctor regarding any medical concerns.
All medicine names, trademarks, and registered trademarks displayed on 5M Biotech India are property of their respective owners. 5M Biotech India and its operator are not affiliated with, endorsed by or authorized by any such trademark owners unless stated expressly. Any reference to trademarks or product names is made for informational purposes. No sponsorship, commercial relationship, approval or association with any trademark owner should be inferred. Information provided herein does not constitute advertising, promotion or an offer for sale of any medicinal goods and is intended solely for general informational purposes.
All trademarks, trade names, and brand names displayed on this website are used strictly in accordance with the applicable provisions of the Trade Marks Act, 1999, including Sections 30 and 30(1) relating to permitted and fair use. The respective trademark ownership has been duly and accurately identified under the “Manufacturer/TM Owner” section in compliance with applicable statutory requirements.
